---
document_datetime: 2025-12-02 05:03:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tecfidera.html
document_name: tecfidera.html
version: success
processing_time: 0.1125836
conversion_datetime: 2025-12-26 12:48:27.871441
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tecfidera

[RSS](/en/individual-human-medicine.xml/65441)

##### Authorised

This medicine is authorised for use in the European Union

dimethyl fumarate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tecfidera](#news-on)
- [More information on Tecfidera](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tecfidera is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. It is used in adults and children from 13 years of age with a type of MS known as relapsing-remitting MS, where the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).

Tecfidera contains the active substance dimethyl fumarate.

Expand section

Collapse section

## How is Tecfidera used?

Tecfidera can only be obtained with a prescription and treatment should be started under the supervision of a doctor experienced in treating MS.

Tecfidera is available as capsules to be taken by mouth with food. The dose is 120 mg twice a day for the first seven days, after which it is increased to 240 mg twice a day. The dose may be reduced temporarily in patients experiencing side effects of flushing and gastrointestinal (stomach and gut) problems.

For more information about using Tecfidera, see the package leaflet or contact your doctor or pharmacist.

## How does Tecfidera work?

In MS, the immune system (the body's natural defences) malfunctions and attacks parts of the central nervous system (the brain, spinal cord and the optic nerve of the eye), causing inflammation that damages the nerves and the insulation around them. The active substance, dimethyl fumarate, is thought to work by activating a protein called 'Nrf2' that regulates certain genes that produce 'antioxidants' involved in protecting cells from damage. Dimethyl fumarate, has been shown to reduce inflammation and modulate the activity of the immune system.

## What benefits of Tecfidera have been shown in studies?

Tecfidera has been shown to reduce the risk of relapses and how often they occur in adults with relapsing-remitting MS. In a main study involving 1,234 adults, the proportion of patients who experienced a relapse over the course of two years was significantly lower with Tecfidera treatment than with placebo (a dummy treatment): 27% versus 46%.

In a second main study involving 1,417 adults, patients were given Tecfidera, placebo or another medicine for MS, glatiramer acetate. This study showed Tecfidera to be more effective than placebo in reducing the number of relapses over the course of two years: the number of relapses per patient per year was around 0.2 with Tecfidera compared with 0.4 with placebo. The number of relapses per patient per year for glatiramer acetate was 0.3.

A main study involving 150 children and adolescents aged 10 to 17 years compared the effects of Tecfidera with interferon beta-1a (another MS medicine). After two years of treatment, around 13% of children taking Tecfidera had no new or newly enlarged lesions (damaged areas) in the brain, compared with around 3% of children in the interferon group. Since there were very few 10- to 12-year-old children in the study, it was not possible to determine the safety of Tecfidera in these young patients, and use of the medicine is therefore recommended from the age of 13.

## What are the risks associated with Tecfidera?

The most common side effects with Tecfidera (which may affect more than 1 in 10 people) are flushing (reddening of skin) and gastrointestinal problems (such as diarrhoea, nausea, and pain in the abdominal area). These side effects tend to start early during treatment, usually in the first month, and may continue intermittently throughout treatment.

Tecfidera must not be used in patients who have or might have progressive multifocal leukoencephalopathy (PML), a serious brain infection that has been associated with some MS medicines.

For the full list of side effects and restrictions with Tecfidera, see the package leaflet.

## Why is Tecfidera authorised in the EU?

Tecfidera has been shown to be effective in reducing the risk of relapses in adults with relapsing-remitting MS and how often they occur, and in reducing the risk of new lesions appearing or existing lesions becoming larger in children and adolescents from 13 years of age. The main risks identified with Tecfidera are considered to be manageable and include flushing and gastrointestinal problems (the most common side effects), as well as reduced levels of white blood cells, and protein in the urine.

The European Medicines Agency therefore decided that Tecfidera's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tecfidera?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tecfidera have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tecfidera are continuously monitored. Side effects reported with Tecfidera are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tecfidera

Tecfidera received a marketing authorisation valid throughout the EU on 30 January 2014.

Tecfidera : EPAR - Medicine overview

Reference Number: EMA/62880/2022

English (EN) (112.97 KB - PDF)

**First published:** 26/02/2014

**Last updated:** 25/05/2022

[View](/en/documents/overview/tecfidera-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-888)

български (BG) (136.55 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/bg/documents/overview/tecfidera-epar-medicine-overview_bg.pdf)

español (ES) (112.1 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/es/documents/overview/tecfidera-epar-medicine-overview_es.pdf)

čeština (CS) (134.48 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/cs/documents/overview/tecfidera-epar-medicine-overview_cs.pdf)

dansk (DA) (111.51 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/da/documents/overview/tecfidera-epar-medicine-overview_da.pdf)

Deutsch (DE) (114.87 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/de/documents/overview/tecfidera-epar-medicine-overview_de.pdf)

eesti keel (ET) (100.54 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/et/documents/overview/tecfidera-epar-medicine-overview_et.pdf)

ελληνικά (EL) (136.02 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/el/documents/overview/tecfidera-epar-medicine-overview_el.pdf)

français (FR) (113.7 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/fr/documents/overview/tecfidera-epar-medicine-overview_fr.pdf)

hrvatski (HR) (133.67 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/hr/documents/overview/tecfidera-epar-medicine-overview_hr.pdf)

italiano (IT) (110.95 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/it/documents/overview/tecfidera-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (149.72 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/lv/documents/overview/tecfidera-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (133.62 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/lt/documents/overview/tecfidera-epar-medicine-overview_lt.pdf)

magyar (HU) (134.92 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/hu/documents/overview/tecfidera-epar-medicine-overview_hu.pdf)

Malti (MT) (136.54 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/mt/documents/overview/tecfidera-epar-medicine-overview_mt.pdf)

Nederlands (NL) (112.16 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/nl/documents/overview/tecfidera-epar-medicine-overview_nl.pdf)

polski (PL) (135.05 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/pl/documents/overview/tecfidera-epar-medicine-overview_pl.pdf)

português (PT) (113.1 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/pt/documents/overview/tecfidera-epar-medicine-overview_pt.pdf)

română (RO) (132.36 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/ro/documents/overview/tecfidera-epar-medicine-overview_ro.pdf)

slovenčina (SK) (133.56 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/sk/documents/overview/tecfidera-epar-medicine-overview_sk.pdf)

slovenščina (SL) (131.58 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/sl/documents/overview/tecfidera-epar-medicine-overview_sl.pdf)

Suomi (FI) (110.39 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/fi/documents/overview/tecfidera-epar-medicine-overview_fi.pdf)

svenska (SV) (110.59 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

25/05/2022

[View](/sv/documents/overview/tecfidera-epar-medicine-overview_sv.pdf)

Tecfidera : EPAR - Risk Management Plan

English (EN) (1.33 MB - PDF)

**First published:** 30/11/2022

**Last updated:** 26/09/2024

[View](/en/documents/rmp/tecfidera-epar-risk-management-plan_en.pdf)

## Product information

Tecfidera : EPAR - Product Information

English (EN) (155.23 KB - PDF)

**First published:** 26/02/2014

**Last updated:** 06/01/2025

[View](/en/documents/product-information/tecfidera-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-99)

български (BG) (292.15 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/bg/documents/product-information/tecfidera-epar-product-information_bg.pdf)

español (ES) (164.77 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/es/documents/product-information/tecfidera-epar-product-information_es.pdf)

čeština (CS) (205.75 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/cs/documents/product-information/tecfidera-epar-product-information_cs.pdf)

dansk (DA) (157.96 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/da/documents/product-information/tecfidera-epar-product-information_da.pdf)

Deutsch (DE) (167.4 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/de/documents/product-information/tecfidera-epar-product-information_de.pdf)

eesti keel (ET) (161.42 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/et/documents/product-information/tecfidera-epar-product-information_et.pdf)

ελληνικά (EL) (302.04 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/el/documents/product-information/tecfidera-epar-product-information_el.pdf)

français (FR) (171.34 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/fr/documents/product-information/tecfidera-epar-product-information_fr.pdf)

hrvatski (HR) (185.43 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/hr/documents/product-information/tecfidera-epar-product-information_hr.pdf)

íslenska (IS) (162.81 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/is/documents/product-information/tecfidera-epar-product-information_is.pdf)

italiano (IT) (164.3 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/it/documents/product-information/tecfidera-epar-product-information_it.pdf)

latviešu valoda (LV) (229.42 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/lv/documents/product-information/tecfidera-epar-product-information_lv.pdf)

lietuvių kalba (LT) (212.48 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/lt/documents/product-information/tecfidera-epar-product-information_lt.pdf)

magyar (HU) (193.03 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/hu/documents/product-information/tecfidera-epar-product-information_hu.pdf)

Malti (MT) (208.42 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/mt/documents/product-information/tecfidera-epar-product-information_mt.pdf)

Nederlands (NL) (164.95 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/nl/documents/product-information/tecfidera-epar-product-information_nl.pdf)

norsk (NO) (154.55 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/no/documents/product-information/tecfidera-epar-product-information_no.pdf)

polski (PL) (223.85 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/pl/documents/product-information/tecfidera-epar-product-information_pl.pdf)

português (PT) (162.79 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/pt/documents/product-information/tecfidera-epar-product-information_pt.pdf)

română (RO) (271.19 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/ro/documents/product-information/tecfidera-epar-product-information_ro.pdf)

slovenčina (SK) (194.11 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/sk/documents/product-information/tecfidera-epar-product-information_sk.pdf)

slovenščina (SL) (175.96 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/sl/documents/product-information/tecfidera-epar-product-information_sl.pdf)

Suomi (FI) (164.38 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/fi/documents/product-information/tecfidera-epar-product-information_fi.pdf)

svenska (SV) (159.94 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

06/01/2025

[View](/sv/documents/product-information/tecfidera-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0088 18/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tecfidera : EPAR - All Authorised presentations

English (EN) (24.97 KB - PDF)

**First published:** 26/02/2014

**Last updated:** 23/12/2014

[View](/en/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-469)

български (BG) (26.85 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/bg/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_bg.pdf)

español (ES) (24.03 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/es/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_es.pdf)

čeština (CS) (24.49 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/cs/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (24.9 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/da/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (24.69 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/de/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (23.99 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/et/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (25.67 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/el/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_el.pdf)

français (FR) (23.06 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/fr/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.01 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/hr/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (24.06 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/is/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_is.pdf)

italiano (IT) (23.05 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/it/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (24.95 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/lv/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (26.19 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/lt/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (24.63 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/hu/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (25.5 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/mt/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (24.58 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/nl/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (23.82 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/no/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_no.pdf)

polski (PL) (25.57 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/pl/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_pl.pdf)

português (PT) (24.04 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/pt/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_pt.pdf)

română (RO) (24.03 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/ro/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (24.66 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/sk/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (23.54 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/sl/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (23.2 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/fi/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (24.15 KB - PDF)

**First published:**

26/02/2014

**Last updated:**

23/12/2014

[View](/sv/documents/all-authorised-presentations/tecfidera-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tecfidera International non-proprietary name (INN) or common name dimethyl fumarate Therapeutic area (MeSH) Multiple Sclerosis Anatomical therapeutic chemical (ATC) code L04AX07

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).

## Authorisation details

EMA product number EMEA/H/C/002601 Marketing authorisation holder

Biogen Netherlands B.V.

Prins Mauritslaan 13 1171 LP Badhoevedorp The Netherlands

Opinion adopted 21/03/2013 Marketing authorisation issued 30/01/2014 Revision 32

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tecfidera : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (243.69 KB - PDF)

**First published:** 11/08/2014

**Last updated:** 06/01/2025

[View](/en/documents/procedural-steps-after/tecfidera-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tecfidera-H-C-2601-P46-023 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/168117/2023

English (EN) (344.58 KB - PDF)

**First published:** 20/04/2023

[View](/en/documents/variation-report/tecfidera-h-c-2601-p46-023-epar-assessment-report_en.pdf)

Tecfidera : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/CHMP/45040/2022

English (EN) (118.76 KB - PDF)

**First published:** 25/05/2022

[View](/en/documents/pip-compliance/tecfidera-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Tecfidera-H-C-2601-II-0073 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/260961/2022

English (EN) (5.7 MB - PDF)

**First published:** 25/05/2022

[View](/en/documents/variation-report/tecfidera-h-c-2601-ii-0073-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Tecfidera (II-0073)

Adopted

Reference Number: EMA/CHMP/691024/2021 Rev.2

English (EN) (129.75 KB - PDF)

**First published:** 28/01/2022

**Last updated:** 22/04/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tecfidera-ii-0073_en.pdf)

Tecfidera-H-C-PSUSA-00010143-202103 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/730120/2021

English (EN) (113.4 KB - PDF)

**First published:** 14/01/2022

[View](/en/documents/scientific-conclusion/tecfidera-h-c-psusa-00010143-202103-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Tecfidera-H-C-PSUSA-00010143-201903 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/689907/2019

English (EN) (141.1 KB - PDF)

**First published:** 15/01/2020

[View](/en/documents/scientific-conclusion/tecfidera-h-c-psusa-00010143-201903-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Tecfidera-H-C-2601-II-0059 : Assessment Report - Variation

Reference Number: EMA/530840/2019

English (EN) (151.9 KB - PDF)

**First published:** 27/09/2019

**Last updated:** 16/10/2019

[View](/en/documents/variation-report/tecfidera-h-c-2601-ii-0059-assessment-report-variation_en.pdf)

Tecfidera-H-C-2601-P46-020 : Assessment Report

Adopted

Reference Number: EMA/413345/2019

English (EN) (263.38 KB - PDF)

**First published:** 19/07/2019

[View](/en/documents/variation-report/tecfidera-h-c-2601-p46-020-assessment-report_en.pdf)

## Initial marketing authorisation documents

Tecfidera : EPAR - Public assessment report

Adopted

Reference Number: EMA/800904/2013

English (EN) (6.75 MB - PDF)

**First published:** 26/02/2014

**Last updated:** 26/02/2014

[View](/en/documents/assessment-report/tecfidera-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tecfidera

Adopted

Reference Number: EMA/167897/2013/Rev. 2

English (EN) (74.77 KB - PDF)

**First published:** 22/03/2013

**Last updated:** 27/11/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tecfidera_en.pdf)

#### News on Tecfidera

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022) 22/04/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022) 25/02/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022) 28/01/2022

[Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera](/en/news/updated-recommendations-minimise-risk-rare-brain-infection-pml-tecfidera) 23/10/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 October 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-october-2015) 23/10/2015

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 November 2014](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-november-2014) 07/11/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 November 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-november-2013) 22/11/2013

#### More information on Tecfidera

- [EMEA-000832-PIP01-10-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000832-pip01-10-m05)
- [Tecfidera - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/tecfidera)
- [An Observational Study Utilising Data From Big MS Data Registries to Evaluate the Long-Term Safety of Vumerity and Tecfidera - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000285)
- [A target trial emulation with an extension to subgroups: an example for relapsing-remitting multiple sclerosis - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000135)
- [A Retrospective, Multi-Center, Observational Study to Assess the Effect of Tecfidera® Delayed-Release Capsules on Lymphocyte Subsets in Subjects with Relapsing Forms of Multiple Sclerosis (REALIZE) - post-authorisation study](https://catalogues.ema.europa.eu/study/29107)
- [Patient real-world clinical, neurological, tolerability, and safety outcomes for Tecfidera® and Rebif®: A retrospective study (PROTRACT) - post-authorisation study](https://catalogues.ema.europa.eu/study/26260)

**This page was last updated on** 06/01/2025

## Share this page

[Back to top](#main-content)